Evidence map›Paper›PMID 40959537›Full record

ArticleIBRO neuroscience reports2025

The miR-133b and miR-206 serum levels as a candidate biomarker in Alzheimer's patients with dyslipidemia.

Shahram Darabi, Enam Alhagh Gorgich, Auob Rustamzadeh, Nafiseh Mohebi, Hossein Mozhdehipanah

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in IBRO neuroscience reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Shahram DarabiCellular and Molecular Research Center, Research Institute for Prevention of Non-communicable Diseases, Qazvin University of Medical Sciences, Qazvin, Iran.
Enam Alhagh GorgichDepartment of Anatomy, School of Medicine, Iranshahr University of Medical Sciences, Iranshahr, Iran.
Auob RustamzadehCellular and Molecular Research Center, Research Institute for Prevention of Non-communicable Diseases, Qazvin University of Medical Sciences, Qazvin, Iran.
Nafiseh MohebiDepartment of Neurology, Rasool Akram Hospital, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Hossein MozhdehipanahDepartment of Neurology, BouAliSina Hospital, School of Medicine, Qazvin University of Medical Sciences, Qazvin, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative condition characterized by cognitive decline. Dyslipidemia, a risk factor for AD, may influence the expression of microRNAs (miRs) involved in AD pathogenesis. Thus, the aim of this study was to investigate the effect of dyslipidemia on the expression levels of miR-133b and miR-206 in AD patients with mild cognitive impairment. This study recruited a total of 45 subjects, who were subsequently divided into three distinct groups: the AD group (n = 15), the AD dyslipidemia group (n = 15), and the dyslipidemia group with normal cognitive status (n = 15). The Aβ

Indexed as

Alzheimer's diseaseBiomarkerDyslipidemiaMiR-133bMiR-206

Identifiers

PMID40959537
PMCPMC12434688

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.